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Type I interferons (IFN) have an essential role in antiviral defense, and they are produced upon viral infection in a
variety of cells. IFN-a/b treatment of immature dendritic cells (DC) is known to induce their phenotypic and func-
tional maturation, but it remains unclear whether stimulation by this cytokine family inﬂuences the functions and
maturation of Langerhans cells (LC). We used highly enriched (495%) LC directly isolated from BALB/c mouse skin
and addressed this issue, comparing LC with splenic CD11cþ DC. Type I IFN-treated LC exhibited impaired ability
to produce IL-12 and inﬂammatory cytokines, IL-6 and TNF-a, whereas IL-10 production was not augmented. In
splenic DC, the production of inﬂammatory cytokines was rather enhanced by type I IFN treatment. With regard to
chemokines, in both LC and splenic DC, type I IFN upregulated the production of inﬂammatory chemokines, such
as CXCL10, CXCL11, CCL3, CCL4, and CCL5. Strikingly, IFN-b treatment reduced the expression of CD40, CD54,
CD80, and CD86 on LC, whereas IFN-b-treated splenic DC showed enhanced expression of these molecules. Fur-
thermore, IFN-b-treated LC had impaired costimulatory activity for anti-CD3-induced proliferation of T cells. Finally,
treatment with IFN-a/b reduced the migratory capacity of LC to CCL21. These results indicate that type I IFN inhibit
maturation and activation of LC in a direct manner. Our observations may provide a novel explanation for the
reported inability of LC to act as potent antigen-presenting cells in cutaneous and mucosal viral infection.
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Dendritic cells (DC) comprise a large heterogenous family of
leukocytes and function as professional antigen-presenting
cells (APC) (Caux et al, 2000; Liu, 2001). They are distrib-
uted in all tissues, especially in those providing an environ-
mental interface. DC exist as some distinct subsets that
differ in their ontogeny, surface molecule expression, and
biological function (Liu, 2001; Grohmann et al, 2003). La-
ngerhans cells (LC) are a member of DC that constitute 1%–
3% of epidermal cells (Katz et al, 1979). In common with the
other DC subsets, LC up-regulate their expression of MHC
class II and costimulatory molecules upon activation to be-
come mature DC and migrate to the T cell areas of regional
lymph nodes (LN), where they initiate T cell-dependent im-
mune responses (Stingl et al, 1980; Schuler and Steinman,
1985; Banchereau and Steinman, 1998). At the same time,
LC are endowed with some characteristics different from
the other DC subpopulations, including the existence of
Birbeck granules, lack of functional mannose receptors,
expression of E-cadherin, and dependence on TGF-b for
their differentiation (Banchereau and Steinman, 1998; Banc-
hereau et al, 2000; Wu et al, 2001). As for their function, we
have previously reported that the production of IL-12 by LC
is uniquely regulated by keratinocytes (KC)-derived cyto-
kines, GM-CSF and TGF-b (Tada et al, 2000, 2001), and that
LC are not capable of producing interferon-g (Tada et al,
2003). More recently, we have disclosed that LC exhibit
considerably low responsiveness to microbial components
in comparison with splenic DC (Fujita et al, 2004b; Mitsui
et al, 2004; Tada et al, 2004).
Type I interferons (IFN) are a group of cytokines ex-
pressed at low levels under physiologic conditions, but are
induced to high levels by stimuli such as viral infection (Be-
lardelli et al, 1984; Belardelli, 1995). Type I IFN include a
number of evolutionarily conserved proteins encoded by
closely related and linked genes, the major species of which
are multiple subtypes of IFN-a and a single IFN-b (Kirchner,
1984). Their biologic activity is mediated by binding to the
common heterodimeric receptor (type I IFN receptor)
broadly expressed on most cells (Bogdan, 2000; Biron,
2001; Levy, 2002). Although type I IFN were originally char-
acterized by their antiviral activity and effects on cells of the
innate responses, they are also endowed with biologically
important immunoregulatory activities, thereby playing an
important role in linking innate and adaptive immune re-
sponses (Biron, 2001; Belardelli and Ferrantini, 2002). One
of those activities is their effect on DC function. Indeed, type
I IFN promote maturation and activation of DC generated
from human peripheral blood or mouse bone marrow pre-
cursors, freshly isolated CD11cþ DC from human periph-
eral blood, and also murine splenic CD11cþ DC (Luft et al,
1998; Paquette et al, 1998; Gallucci et al, 1999; Radvanyi
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et al, 1999; Santini et al, 2000; Ito et al, 2001; Parlato et al,
2001; Montoya et al, 2002).
Recently, using a mouse model, two independent groups
have elucidated that LC cannot prime T cell-dependent im-
mune responses in cutaneous and mucosal viral infection
caused by herpes simplex virus (HSV)-1/2 (Allan et al, 2003;
Zhao et al, 2003), but the underlining mechanism has not
been illustrated. In particular, immunomodulatory activities
of type I IFN on resident LC remain totally unexplored.
Therefore, in this study, we investigated how type I IFN
regulated the functional properties of mouse LC. We pre-
pared highly purified LC (495%) using classical panning
technique that had proven to be very useful in exploring the
function of resident LC (Salgado et al, 1999b; Tada et al,
2000). We used these purified LC for our in vitro system to
examine the effects of type I IFN on maturation and acti-
vation of LC in comparison with splenic CD11cþ DC. We
demonstrated that epidermal LC also differ remarkably from
the other DC subsets in terms of their responsiveness to
type I IFN.
Results
Effects of IFN-a/b on IL-12p40 and IL-6 production in-
duced by IFN-c and anti-CD40 Ab in LC and splenic
DC We have previously shown that LC stimulated with anti-
CD40 Ab and IFN-g produce a large amount of IL-12p40
protein (Tada et al, 2000, 2001). In addition, it is reported
that IFN-b downregulates CD40 ligation-induced IL-12 p40
and p70 production by myeloid DC (Bartholome et al, 1999;
Huang et al, 2000; McRae et al, 2000). Therefore, we first
examined the effects of IFN-a/b on IL-12p40 production by
anti-CD40 Ab/IFN-g-stimulated LC and splenic CD11cþ
DC. Increasing concentrations (10–10,000 U per mL) of IFN-
a or IFN-b were added to the culture medium, together with
anti-CD40 Ab and IFN-g. As shown in Fig 1, higher doses of
IFN-a/b completely blocked IL-12p40 production by stim-
ulated LC and partially inhibited that by stimulated splenic
DC.
We next studied the effects of IFN-a/b on the production
of the inflammatory cytokine IL-6. Similar to IL-12p40, the
IL-6 protein was abundantly secreted in the supernatant of
anti-CD40 Ab/IFN-g-stimulated LC and splenic DC (Fig 2).
IFN-a/b decreased IL-6 production by stimulated LC in
a concentration-dependent manner. In contrast, they in-
creased the production of IL-6 by splenic DC treated in the
same way as LC. The data obtained from splenic DC were
consistent with those obtained from human DC reported by
other investigators (McRae et al, 2000).
There still remains the possibility that type I IFN may have
inhibited the survival of LC in culture, since they sharply
suppressed the production of both IL-12p40 and IL-6 by
LC. To exclude this possibility, we assessed the cell viability
of 24 and 48 h cultured LC. Neither IFN-a (1000 U per mL)
nor IFN-b (1000 U per mL) affected the cell viability of cul-
tured LC (data not shown). These results suggest that IFN-
a/b function at a level distinct from in vitro cell survival.
IFN-a/b inhibit bioactive IL-12 production by primed
LC It is well known that the level of IL-12p40 does not
necessarily correlate with the bioactivity of IL-12 (Trinchieri,
2003). Therefore, we used a bioassay using an IL-12-de-
pendent cell line 2D6 and evaluated the effect of IFN-a/b on
bioactive IL-12p70 heterodimer production by LC, as pre-
viously described (Tada et al, 2000). As shown in Fig 3, both
IFN-a and IFN-b, at a dose of 1000 U per mL, significantly
downregulated the production of bioactive IL-12 by anti-
CD40 Ab/IFN-g-stimulated LC, indicating that the level of
IL-12p40 production correlated with that of bioactive IL-
12p70.
Effects of IFN-a/b on the production of other cytokines
by LC and splenic DC Table I shows the effects of IFN-a/b
Figure 1
Interferon (IFN)-a/b decrease anti-CD40 Ab/IFN-c-primed IL-12p40
production by 48 h cultured Langerhans cells (LC) and splenic
dendritic cells (DC). LC and splenic DC (1.5  106 per mL) were cul-
tured for 48 h with anti-CD40 Ab (20 mg per mL), IFN-g (100 ng per mL),
and increasing concentrations of IFN-a/b. Culture supernatants were
collected, and concentration of the IL-12p40 was measured by ELISA
(n¼ 4). Representative data of three independent experiments are
shown.
Figure2
Interferon (IFN)-a/b decrease anti-CD40 Ab/IFN-c-primed IL-6 pro-
duction by Langerhans cells (LC) and increase that by splenic
dendritic cells (DC). LC and splenic DC (1.5  106 per mL), were cul-
tured for 48 h with anti-CD40 Ab (20 mg per mL), IFN-g (100 ng per mL)
and increasing concentrations of IFN-a/b. Culture supernatants were
collected, and the concentration of IL-6 was measured by ELISA
(n¼4). Representative data of three independent experiments are
shown.
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on the production of various cytokines other than IL-12 and
IL-6 by LC and splenic DC, respectively. LC and splenic DC
were cultured with or without IFN-a/b (1000 U per mL), and
culture supernatants were harvested after 48 h. The pro-
duction of IL-1b, IL-10, and TNF-a by these cells were de-
termined by ELISA. The production of TNF-a by LC was
decreased in the presence of IFN-a/b. On the other hand,
IFN-a/b did not modulate the production of IL-1b and IL-10
by LC. In the case of splenic DC, IFN-a/b augmented the
amount of TNF-a production, and did not affect the pro-
duction of IL-1b and IL-10.
Effects of IFN-a/b on the production of chemokines by
LC and splenic DC Recently, we have demonstrated that
LC are also capable of producing various chemokines like
other DC subsets (Xiao et al, 2003; Fujita et al, 2004a, 2005).
Therefore, in this study, culture supernatants of LC and
splenic DC, treated with or without IFN-a/b, were subjected
to the measurement of the levels of CCL3, CCL4, CCL5,
CCL17, CCL22, CXCL9, CXCL10, and CXCL11 as de-
scribed in Materials and Methods. As shown in Table I, the
production of CCL17 and CCL22 by LC was downregulated
by IFN-a/b. On the contrary, IFN-a/b augmented the pro-
duction of CCL3, CCL4, CCL5, CXCL10, and CXCL11 by LC
during 48 h culture. Similar results were obtained from
splenic DC. IFN-a/b downregulated the production of
CCL17 and CCL22 by splenic DC, and upregulated that
of CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11
(Table I).
Type I IFN enhance the expression of cell surface mol-
ecules on splenic DC whereas they inhibit that on LC It
is reported that the maturation of DC is driven by stimulation
Figure 3
Interferon (IFN)-a/b inhibit bioactive IL-12 production by anti-CD40
Ab/IFN-c-stimulated Langerhans cells (LC). Purified LC (1.5  106
per mL) were stimulated with anti-CD40 Ab (20 mg per mL) and IFN-g
(100 ng per mL) with or without the presence of IFN-a/b (1000 U per mL)
for 48 h. Culture supernatants were collected and tested for IL-12 ac-
tivity in a bioassay using an IL-12-dependent cell line 2D6 as described
in Materials and Methods. IL-12 bioactivity was expressed as anti-IL-12
(C17.8)-inhibitable [3H]TdR uptake of 2D6. Results are mean  SD
(n¼ 3). #po0.05 compared with [3H]TdR uptake of 2D6 cultured with
supernatants of LC stimulated with anti-CD40 Ab and IFN-g. Repre-
sentative data of three independent experiments are shown.
Table I. Cytokine and chemokine production by LC and splenic DC (pg per mL)a
IL-1b IL-10 TNF-a CCL3 CCL4 CCL5
LC
No stimulation 72.7  7.0 23.9  1.6 86.6  19.4 134.0  10.8 42.3  2.0 901  46
IFN-a 1000 U per mL 63.9  14.1 25.6  1.6 47.7  8.1 221.0  26.6 57.8  4.3 1414  60
IFN-b 1000 U per mL 62.5  6.4 27.2  2.7 41.0  8.3 183.5  14.7 54.8  7.9 1830  209
Splenic DC
No stimulation 19.5  4.1 9.3  1.3 54.2  15.7 64.3  8.7 287  24.6 1373  271
IFN-a 1000 U per mL 21.1  5.5 10.9  1.3 130.2  27.2 238.5  36.8 1325  136.0 5336  1086
IFN-b 1000 U per mL 20.7  4.8 10.9  0.8 142.0  13.1 159.8  40.7 1069.8  180.0 5235  453
CCL17 CCL22 CXCL9 CXCL10 CXCL11
LC
No stimulation 1333  10.6 68,386  1256 43.4  6.8 2598  50 33.6  3.3
IFN-a 1000 U per ml 302  11.7 29,149  2759 40.0  3.3 8783  681 74.9  7.1
IFN-b 1000 U per mL 177  7.1 21,730  2167 38.7  4.6 10,681  270 145.5  1.7
Splenic DC
No stimulation 27.4  3.2 3647  372 47.7  1.7 2542  107 33.6  3.3
IFN-a 1000 U per mL 12.7  0.1 1572  367 146.8  5.3 28,436  5933 74.9  7.1
IFN-b 1000 U per mL 13.0  1.2 1480  282 221.6  10.9 27,179  6438 145.5  1.7
aPurified LC and splenic DC (1.5  106 per mL) were cultured for 48 h with or without 1000 U per mL of IFN-a/b. The supernatants were collected and
the concentrations of various cytokines and chemokines indicated in the table were measured by ELISA as described in Materials and methods. All
results are expressed as mean  SD of four independent experiments performed in duplicated.
Significant increase (po0.05) compared with unstimulated group.
Significant decrease (po0.05) compared with unstimulated group.
LC, Langerhans cells; DC, dendritic cells.
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with type I IFN (Luft et al, 1998; Paquette et al, 1998; Gall-
ucci et al, 1999; Radvanyi et al, 1999; Santini et al, 2000; Ito
et al, 2001; Parlato et al, 2001; Montoya et al, 2002). We
studied whether this was also the case with LC. We have
previously shown that purified LC in our preparation acquire
mature phenotypes during culture periods and come to ex-
press CD40, CD54, CD80, CD86, and a higher level of I-Ad
(Salgado et al, 1999a,b; Tada et al, 2000, 2001). To deter-
mine whether IFN-a/b affect maturation of LC and splenic
DC, these cells were cultured with or without IFN-b, and
harvested after 48 h to examine the expression of surface
molecules by FACS analysis. We found that IFN-b further
upregulated I-Ad, CD40, CD54, CD80, and CD86 expression
in splenic DC (Fig 4), which was consistent with the findings
by Montoya et al (2002) in mouse splenic DC. On the con-
trary, the expression of CD40, CD54, CD80, and CD86 on
LC was inhibited by IFN-b stimulation (Fig 4). No remarkable
change in I-Ad expression was observed. It was indicated,
therefore, that the inhibitory effect of IFN-b on the expres-
sion of surface molecules associated with maturation was
characteristic of LC among DC lineage. Similarly, we ex-
amined the effect of IFN-a on LC and splenic DC, and found
that its effect was the same and significant, albeit slightly
weaker than that of IFN-b (data not shown). We then ex-
amined the surface expression of TNF-related apoptosis-
inducing ligand (TRAIL), since IFN-b was reported to induce
TRAIL in human monocyte-derived DC (Liu et al, 2001;
Vidalain et al, 2001). Indeed, IFN-b- or IFN-a-stimulated
splenic CD11cþ DC expressed TRAIL on cell the surface
after 16 h culture (Fig 5). In contrast, TRAIL expression
could not be detected in IFN-b- or IFN-a-stimulated LC at
any time point of culture period (12, 16, 24, and 48 h) (Fig 5
and data not shown).
IFN-b upregulates costimulatory activity of splenic DC
whereas it downregulates that of LC To elucidate wheth-
er the negative modulation of cell surface molecules on LC
caused by IFN-b affected functional activity of LC, we ex-
amined the costimulatory capacity of unstimulated and IFN-
b-treated LC in comparison with that of splenic DC. Forty-
eight hour cultured LC and splenic DC with or without 1000
U per mL of IFN-b were fixed with paraformaldehyde, and
then they were assessed for costimulatory activity for anti-
CD3-induced proliferation of T cells isolated from BALB/c
mouse spleen. As shown in Fig 6, IFN-b treatment further
enhanced the costimulatory function of splenic DC. In con-
trast, the stimulatory effect of IFN-b-treated LC was signif-
icantly lower than that of unstimulated LC. These data
indicate that IFN-b inhibited the costimulatory function of
LC through negative modulation of surface molecules.
Figure 4
Interferon (IFN)-b upregulates the expression of cell surface mol-
ecules of splenic dendritic cells (DC) and downregulates that of
Langerhans cells (LC). Purified LC and splenic DC were cultured with
or without IFN-b (1000 U per mL) for 48 h. I-Ad, CD40, CD80, and CD86
levels of unstimulated and IFN-b-treated LC and splenic DC were
analyzed using flow cytometry. Broken lines, isotype control; dotted
lines, unstimulated cells; solid lines, IFN-b-stimulated cells. Mean flu-
orescence intensity of unstimulated versus IFN-b-stimulated LC: I-Ad,
1375 vs 1273; CD40, 989 vs 679; CD54, 634 vs 544; CD80, 320 vs 189;
CD86, 893 vs 692. Mean fluorescence intensity of unstimulated versus
IFN-b-stimulated DC: I-Ad, 329 vs 511; CD40, 73 vs 85; CD54, 69 vs 87;
CD80, 77 vs 157; CD86, 92 vs 136. The figure shows one of three
representative experiments with similar results.
Figure5
Interferon (IFN)-a/b induce TNF-related apoptosis-inducing ligand
(TRAIL) expression in splenic dendritic cells (DC) but not in La-
ngerhans cells (LC). Purified LC and splenic DC were cultured with or
without IFN-a/b (5000 U per mL) for 16 h. TRAIL levels of unstimulated
and IFN-a/b-treated cells were analyzed using flow cytometry. Dotted
lines, isotype control; solid lines, anti-TRAIL mAb. When stimulated
with IFN-a or IFN-b for 16 h, TRAIL expression was induced in splenic
DC. But TRAIL expression was not detected in LC, regardless of the
addition of IFN-a or IFN-b. The figure shows one of three representative
experiments with similar results.
Figure6
Interferon (IFN)-b enhances costimulatory activity of splenic den-
dritic cells (DC) and inhibits that of Langerhans cells (LC). Fixed
BALB/c LC or splenic DC (1  104) pre-cultured for 48 h with or without
1000 U per mL IFN-b were added to purified BALB/c spleen T cells
(1  105) and cultured for 96 h. [3H]TdR was added during the final 16 h
of culture. #Significant decrease (po0.05) of [3H]TdR uptake of T cells
cultured with IFN-b-treated LC compared with that of T cells cultured
with untreated LC. Significant increase (po0.05) of [3H]TdR uptake of
T cells cultured with IFN-b treated splenic DC compared with that of T
cells cultured with untreated splenic DC. Each result is the mean  SD
of triplicate determination from one of three similar experiments.
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Type I IFN promote chemotactic capacity of splenic DC
to CCL21, whereas they impair that of LC Acquisition of
CCR7 expression is an important phenotypic change during
the maturation of DC, allowing them to migrate to draining
LN (Banchereau et al, 2000). Indeed, freshly isolated imma-
ture LC neither express mRNA for CCR7 nor respond to
CCR7 ligands, whereas 24 h cultured mature LC express
CCR7 mRNA and exhibit migratory capacity to CCL19 and
CCL21, peaking at 10 nM.1 Using a chemotaxis assay, we
investigated the effect of type I IFN on the responsiveness
of 24 h cultured LC and splenic DC to the CCR7 ligand
CCL21. As shown in Fig 7, LC and splenic DC cultured for
24 h without stimulation exhibited comparable migratory
capacity to CCL21 (10 nM). IFN-a/b (1000 U per mL) treat-
ment promoted the migration of splenic DC to CCL21, but
inhibited that of LC.
Discussion
In a series of experiments presented here, we explored the
physiological significance of type I IFN on LC. For this pur-
pose, we obtained highly purified (495%) LC directly from
BALB/c mouse skin. This study has been performed using
resident LC. We found that type I IFN suppressed the mat-
uration of LC and inhibited the production of IL-12 and in-
flammatory cytokines. IFN-b-treated LC also exhibited
impaired costimulatory activity. As for chemokine produc-
tion by LC, type I IFN augmented the production of many
types of inflammatory chemokines.
The fact that IL-12 production by LC was inhibited by
type I IFN was consistent with the finding in conventional
DC (Colonna et al, 2002). Type I IFN, however, also inhibited
the production of inflammatory cytokines, such as IL-6 and
TNF-a, by LC. Unlike the case of IL-12, this inhibition was
not observed in splenic DC, and was considered to be
characteristic of LC. One possible explanation was that
type I IFN might have induced IL-10 production in LC. In-
deed, IFN-b has been shown to inhibit IL-12 production in
human blood mononuclear cells in an IL-10-dependent
manner (Wang et al, 2000). Furthermore, Ito et al reported
that in human blood CD11cþ myeloid DC, IFN-a dramat-
ically induced IL-10 production and antagonized IFN-g-in-
duced IL-12 production, leading to the assumption that the
defeating action of IFN-a on IFN-g-mediated stimulation
might be partly ascribed to IL-10 production by DC them-
selves (Ito et al, 2001). As shown here, however, type I IFN
failed to induce IL-10 production in mouse LC. Therefore,
we concluded that the inhibitory effect of IFN-a/b on the
activation of LC in our system was not mediated by IL-10,
but was a direct action. Importantly, IFN-b-stimulated LC
exhibited lower expression of costimulatory molecules and
impaired costimulatory activity compared with unstimulated
LC. Although the inhibition of each costimulatory molecule
was modest, T lymphocyte proliferation was markedly re-
duced. It is therefore possible that molecules other than
those investigated here on LC could be involved in the re-
duction of T cell proliferation. This unique regulation is also
thought to be characteristic of LC, since type I IFN are
generally known to enhance the expression of costimulatory
molecules on DC and to enhance the ability of DC to stim-
ulate T cells (Biron, 2001; Bon and Tough, 2002). Further,
slight prevention of chemotactic activity of LC to CCL21, in
contrast to that of splenic DC, supports the idea that type I
IFN inhibit their maturation. Their reduced chemotaxis
suggests that type I IFN suppressed CCR7 expression of
LC, but we could not detect a significant change of CCR7
mRNA expression by RT-PCR analysis (data not shown).
In addition, the inability of LC to express TRAIL is another
example of functional diversity between LC and the
other DC subsets with respect to the responsiveness to
IFN-a/b.
It is well established that the major cell type producing
type I IFN is plasmacytoid DC, both in humans and in mice.
These cells are capable of producing large amounts of type
I IFN following viral infection (Bon and Tough, 2002; Levy,
2002), and are found predominantly in blood and in the Tcell
area of secondary lymphoid organs (Nakano et al, 2001;
Bon and Tough, 2002; Colonna et al, 2002; O’Keeffe et al,
2003). Myeloid DC are also capable of secreting type I IFN
in response to virus-derived double-stranded RNA (dsRNA)
(Kapsenberg, 2003). In our study, LC, as well as splenic DC,
upregulated IFN-b mRNA expression upon stimulation with
double-stranded RNA, but its production could not be de-
termined at the protein level (Fujita et al, 2004b). In the skin,
fibroblasts and KC are known to secrete type I IFN (Bielenb-
erg et al, 1999; Akbar et al, 2000). Previous studies have
reported high concentrations of IFN-a/b within the vesicle
fluid from lesions of herpes labialis (Spruance et al, 1977;
Overall et al, 1981), consistent with their production by HSV-
infected KC in vitro (Schnipper et al, 1984). Since LC migrate
from the epidermis to draining LN following cutaneous viral
infection, they could be exposed to a large amount of type I
Figure 7
Interferon (IFN)-a/b promote the migration of splenic dendritic cells
(DC) to CCL21 and suppress that of Langerhans cells (LC). Purified
LC and splenic DC were cultured for 24 h with or without 1000 U per mL
of IFN-a/b. Then, cultured LC and splenic DC were tested for CCL21-
triggered migration in transwell assays. Medium alone served as a
negative control. Significant increase (po0.05) of the migration of type
I IFN-treated splenic DC compared with that of untreated splenic DC.
#Significant decrease (po0.05) of the migration of type I IFN-treated LC
compared with that of untreated LC. Results are the mean  SD of
triplicate determination from one of three similar experiments.
1Fujita et al, manuscript in preparation.
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IFN on their way, resulting in alterations of their function by
this cytokine family.
Recently, using a mouse model of vaginal infection with
HSV-2, Zhao et al (2003) demonstrated that LC in the vag-
inal epithelium did not contribute to virus-specific CD4þ T
cell activation (Zhao et al, 2003). Moreover, Allan et al (2003)
showed that LC were incapable of priming HSV-1-specific
CD8þ T cells in vivo. Given that HSV-infected KC produce
type I IFN (Schnipper et al, 1984) and that plasmacytoid DC
exist in the draining LN of HSV infection site (Allan et al,
2003; Yoneyama et al, 2004), it is possible that newly syn-
thesized type I IFN by those cells act on LC directly to
suppress their functional property as APC. Recognition of
microbial components through Toll-like receptors (TLR) is
also involved in antiviral immune responses mediated by DC
(Barton and Medzhitov, 2002). In particular, TLR3, 7, and 9
recognize virus-derived dsRNA, single-stranded RNA, and
CpG DNA, respectively (Akira and Takeda, 2004). The re-
sponsiveness of LC to dsRNA and CpG DNA, however, was
much weaker than that of splenic DC, and the expression of
TLR7 was not at all observed in LC (Fujita et al, 2004b;
Mitsui et al, 2004). Taken together, our data indicate that
type I IFN inhibit maturation and activation of LC, and may,
at least partially, account for the inability of LC to function as
potent APC in the HSV infection model.
With regard to chemokine production, type I IFN-treated
LC upregulated the production of inflammatory chemokines
such as CXCL10, CXCL11, CCL3, CCL4, and CCL5, and
downregulated that of CCL17 and CCL22. Chemokine pro-
files of LC observed in this study were almost consistent
with the observations in mouse splenic DC and human
monocyte-derived DC (Parlato et al, 2001; Padovan et al,
2002). Although the amounts of inflammatory chemokines
produced by IFN-a/b-stimulated LC were less than those by
IFN-a/b-stimulated splenic DC (Table I), increased produc-
tion of inflammatory chemokines by LC in the skin may
promote the recruitment of APC, such as immature DC, or
effector cells, such as natural killer cells, T cells, macroph-
ages, or granulocytes. CXCL9, CXCL10, and CXCL11 share
the common receptor CXCR3, whereas CCL3, CCL4, and
CCL5 share CCR5. With respect to Th1/Th2 paradigm, both
CXCR3 and CCR5 are preferentially expressed on Th1
lymphocytes, whereas CCL17 and CCL22 are ligands for
CCR4 predominantly expressed on Th2 lymphocytes (Sal-
lusto et al, 2000). LC-derived chemokines may also play a
role in regulating the attraction and retention of Th1-prone T
cells in the microenvironment of abundant type I IFN such
as viral infection.
In summary, in this work, we demonstrated that type I
IFN inhibited both maturation and activation of mouse LC,
which seems to be characteristic of LC among DC lineage.
Given that KC and plasmacytoid DC produce type I IFN in
response to HSV (Schnipper et al, 1984; Lund et al, 2003;
Krug et al, 2004), our data presumably account for the in-
ability of LC to act as potent APC in the HSV infection
model. Instead, in case of cutaneous or mucosal viral in-
fection, LC may contribute to immune responses by se-
creting inflammatory chemokines and thus inducing
appropriate cell trafficking. Further studies are necessary
to elucidate the mechanisms responsible for the immuno-
suppressive effects of type I IFN on LC.
Materials and Methods
Mice BALB/c female mice were purchased from Charles River
Japan (Yokohama, Japan) and maintained until 8–12 wk of age
under specific pathogen-free conditions in the Animal Facilities of
the University of Tokyo. All animal experiments were approved by
the Animal research Committee of the University of Tokyo.
Reagents and mAb Mouse rIFN-b and rIFN-aA were purchased
from R&D Systems (Minneapolis, Minnesota). For stimulation of IL-
12 and IL-6 production in mouse LC, mouse rIFN-g was obtained
from R&D Systems, and Rat anti-mouse CD40 mAb (NA/LE, clone
3/23) was purchased from BD Biosciences (San Diego, California).
For flow cytometry, the following mAbs and control isotype-
matched irrelevant mAbs were used for immunostaining: FITC-
conjugated mouse anti-mouse I-Ad, FITC-conjugated hamster
anti-mouse CD40, FITC-conjugated hamster anti-mouse CD54
(ICAM-1), FITC-conjugated hamster anti-mouse CD80 (B7-1),
FITC-conjugated rat anti-mouse CD86 (B7-2), FITC-conjugated
mouse IgG isotype control, FITC-conjugated hamster IgM isotype
control, FITC-conjugated hamster IgG isotype control, FITC-con-
jugated rat IgG1 isotype control, and FITC-conjugated rat IgG2a
isotype control (BD Biosciences). PE anti-mouse TRAIL and PE rat
IgG2a isotype control were obtained from eBioscience (San Diego,
California). For measurement of CCL22 and CXCL10, rCCL22 was
purchased from R&D Systems, and rCXCL10 was provided by
Dako Japan (Kyoto, Japan). Anti-mouse CCL22 and anti-mouse
CXCL10 Abs were obtained from Genzyme/Techne (Cambridge,
Massachusetts). Peroxidase-conjugated rabbit anti-goat IgG Ab
was purchased from MBL (Nagoya, Japan). For a bioassay of IL-
12, mouse rIL-12 was obtained from PeproTech (Rocky Hill, New
Jersey); neutralizing anti-mouse IL-12 mAb (C17.8) and rat IgG
isotype control were purchased from BD Biosciences. For an assay
of costimulatory activity, anti-mouse CD3e mAb (2C11) was ob-
tained from BD Biosciences. For chemotaxis assay, rCCL21 was
provided by R&D Systems.
Puriﬁcation and culture of LC and splenic DC LC were pre-
pared using the previously described panning method, and had a
purity of over 95% as previously shown (Salgado et al, 1999b; Tada
et al, 2000). Briefly, mouse trunkal skin was separated and treated
with dispase (3000 U per mL, Godo Shusei, Tokyo, Japan) in RPMI
medium supplemented with 10% FCS (RPMI 10 medium) for 3 h at
371C. The epidermis was separated and incubated in RPMI 10
medium containing 0.025% deoxyribonuclease I (Sigma, St Louis,
Missouri) for 20 min at room temperature. An epidermal cell sus-
pension was obtained by vigorously pipetting the epidermal
sheets, and it was treated with mouse anti-mouse I-Ad mAb
(1:600; Meiji Seika, Tokyo, Japan) in RPMI 10 medium for 45 min on
ice. The cell suspension in RPMI 10 medium was then incubated in
plates coated with goat anti-mouse IgG (Fc) (1:100; MP Biomed-
icals, Aurora, Ohio) for 45 min at 41C. After the plates had been
washed, adherent cells were collected and designated purified LC.
Splenic DC were purified from spleens of BALB/c mice as de-
scribed previously (Tada et al, 2000, 2001). Briefly, a single-cell
suspension was obtained by gentle teasing with forceps and rub-
bers and filtered through a nylon mesh. Erythrocytes were lysed by
treatment with ammonium chloride. From the remaining unfrac-
tionated cell populations, CD11cþ DC were separated by positive
magnetic selection using microbeads-conjugated hamster anti-
mouse CD11c (Miltenyi Biotec, Belgisch Gladbach, Germany) and
a magnetic cell separator according to the manufacturer’s instruc-
tions, routinely resulting in 490% purity of CD11cþ DC. LC and
splenic DC were incubated in 96-well culture plates (1.5  106
cells per mL per 200 mL in each well) for up to 48 h, with or without
various cytokines and/or Ab in a culture medium that consisted of
RPMI 10 medium, 100 U per mL of penicillin G sodium, 100 mg per
mL of streptomycin sulfate, and 0.25 mg per mL of amphotericin B.
Puriﬁcation of T cell T cells were purified by passage of a single-
cell suspension of BALB/c mice spleen cells over Nylon Fiber Col-
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umn T (Wako Pure Chemical Industries, Osaka, Japan) according
to the manufacturer’s instructions. The purity of T cell preparations
was routinely 495% (CD3eþ by FACS analysis).
Flow cytometric analysis LC and splenic DC cultured for 48 h
with or without IFN-b were resuspended in PBS supplemented with
0.1% BSA and 0.1% NaN3 and divided into tubes for Ab staining.
The cells were incubated with the respective FITC-conjugated mAb
at 1:100 dilution for 30 min at 41C. They were washed twice
by centrifugation after the incubation. The final suspension was
made in 300 ml of PBS supplemented with 0.1% BSA and 0.1%
NaN3 containing propidium iodide to exclude nonviable cells.
Samples were analyzed on a fluorescence-activated cell sorter
(FACSCalibur, BD Biosciences).
Measurement of IL-12p40, IL-6, IL-1b, IL-10, TNF-a, CCL3,
CCL4, CCL5, CCL17, CXCL9, and CXCL11 Culture supernatants
were collected, stored at 201C, and subjected to a quantification
of protein levels of IL-12p40, IL-6, IL-1b, IL-10, TNF-a, CCL3,
CCL4, CCL5, CCL17, CXCL9, and CXCL11 by ELISA using com-
mercially available mouse IL-12p40, IL-6, IL-1b, IL-10, TNF-a,
CCL3, CCL4, CCL5, CCL17, CXCL9, and CXCL11 immunoassay
kits (R&D Systems), respectively, according to the manufacturer’s
instructions. Each sample was tested in duplicate.
Measurement of CCL22 and CXCL10 The concentrations of
CCL22 and CXCL10 in the culture supernatants were measured
by competitive ELISA inhibition assay as previously described
(Kuroda et al, 2001). Briefly, ELISA plates were coated with 100 mL
of CCL22 or CXCL10 at 250 ng per mL in PBS containing 0.1%
BSA at 41C for 18 h. Then, the wells were washed and blocked with
300 mL of RPMI 10 medium at 371C for 30 min. Standard solutions
(40,000–625 pg per mL in RPMI 10 medium) or culture supernat-
ants and equal volumes of 400 ng per mL of anti-CCL22 Ab or 100
ng per mL of anti-CXCL10 Ab were mixed in microtubes and in-
cubated at 371C for 1 h. After the incubation, 200 mL of prepared
standard or sample solutions were transferred to each well of
CCL22- or CXCL10-coated plates, and the plates were kept at 41C
for 18 h. The wells were washed, and 100 mL of peroxidase-con-
jugated rabbit anti-goat IgG Ab (diluted 1:2000 in PBS containing
0.05% Tween 20 and 1% BSA) was added. The plates were in-
cubated at 371C for 2 h. Then, they were washed and 100 mL of
substrate (0.04% o-phenylenediamine, 0.01% H2O2 in 50 mM di-
sodium hydrogen phosphate, and 150 mM citric acid, pH 5) was
added to the wells. The plates were incubated at room temperature
for 30 min. Then, the enzyme reaction was stopped by the addi-
tion of 25 mL of 8 N H2SO4, and the absorbance at 490 nm was
measured.
Bioassay for IL-12 p70 heterodimer The proliferative assay of IL-
12-responsive T cell clone, 2D6, was used as a bioassay for the
active p70 heterodimer (Murano et al, 1997). The entire assay pro-
cedure was performed as previously described (Tada et al, 2000).
In each well of a 96-well microculture plate, 2D6 cells (2.0  104
per well) were incubated in the supernatant of cultured LC or se-
rially diluted standard mouse rIL-12 solutions for 48 h at 371C.
Either 10 mg per mL of rat anti-mouse IL-12 mAb (C17.8) or rat IgG
isotype control was added to each well. The cells were pulse
labeled with 20 kBq per well of [3H]TdR for the final 6 h. All samples
were cultured in duplicate. IL-12 bioactivity of culture supernatants
was determined by subtracting the [3H]TdR uptake of cells incu-
bated with anti-mouse IL-12 mAb (C17.8) from the [3H]TdR uptake
of cells incubated with rat IgG isotype control. Inclusion of control
rat IgG induced negligible effects on IL-12-stimulated 2D6 prolif-
eration.
Assay of LC costimulatory activity The syngeneic stimulation
assay was performed as previously described, with some modi-
fications (Delgado et al, 1999). BALB/c spleen T cells (1  105)
were stimulated in RPMI 10 medium in flat-bottom 96-well plates
with 1  104 BALB/c LC and splenic DC pretreated for 48 h with or
without 1000 U per mL of IFN-b and fixed with 0.5% paraform-
aldehyde, in the presence of soluble anti-CD3 mAb (2C11, 100 ng
per mL) for 4 days at 371C. The cells were pulse labeled with
0.5 mCi [3H] TdR/well for the final 16 h. Proliferation was evaluated
by [3H] TdR uptake of the cells.
Chemotaxis assay Chemotaxis of LC and splenic DC was as-
sessed in 24-well transwells equipped with 5 mM pore polycar-
bonate membranes (Transwell, Corning Costar, Cambridge,
Massachusetts). LC and splenic DC were cultured for 24 h with
or without 1000 U per mL of IFN-a/b. They were collected, and
3  105 cells suspended in 100 mL of RPMI 10 medium were
transferred to the upper chamber. The lower chamber contained
600 mL RPMI 10 medium with or without 10 nM of rCCL21. After an
incubation period of 3 h at 371C, the upper chambers were re-
moved, and the cells in the lower chamber of each well were col-
lected and counted using a Coulter Counter (Beckman Coulter,
Jersey City, New Jersey). All assays were carried out in triplicate.
Statistical analysis Student’s t test was used to analyze the re-
sults, and a p value less than 0.05 was considered statistically
significant.
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